---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076560"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:52:31.188146+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bicara raises $161.8M in public offering; reports preliminary cash of $414.8M

## Summary
- Net proceeds of ~$161.8M from offering of 7.175M shares at $16.00/sh and 2.2M pre-funded warrants.
- Preliminary unaudited cash, cash equivalents and investments as of Dec 31, 2025: ~$414.8M.
- Proceeds to support commercial infrastructure for ficerafusp alfa, accelerated development, and manufacturing.
- Underwriters exercised option for additional 1,406,250 shares.

## SEC filing metadata
- accession: 0001193125-26-076560
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/0001193125-26-076560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/d938194d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076560
- JSON: https://secwatch.observer/filing/0001193125-26-076560.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076560.txt

## Key facts
- Material Agreements
  Bicara Therapeutics Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (effective 2026-02-24).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives
  - Effective: 2026-02-24
  source text: On February 24, 2026, Bicara Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives (the “Representatives”) of the underwriters named therein (the “Underwriters”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/2023658/000119312526076560/0001193125-26-076560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.